Curis (CRIS) Stock Overview
A biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
CRIS Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Curis, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.02 |
| 52 Week High | US$39.00 |
| 52 Week Low | US$3.61 |
| Beta | 3.09 |
| 1 Month Change | -18.54% |
| 3 Month Change | -64.17% |
| 1 Year Change | -88.25% |
| 3 Year Change | -98.51% |
| 5 Year Change | -99.87% |
| Change since IPO | -99.90% |
Recent News & Updates
Narrative Update • Aug 04
CRIS: Future Profitability Will Depend On TakeAim CLL Study Progress
Analysts have lifted their price target on Curis to $43 from $17, citing the added valuation for emavusertib in chronic lymphocytic leukemia following the initiation of the TakeAim study and an assumed 10% probability of success on potential peak sales of $500m. Analyst Commentary Recent research on Curis highlights how much of the current valuation hinges on emavusertib and the new TakeAim study in chronic lymphocytic leukemia.Narrative Update • Jul 20
CRIS: Future Profitability Execution Will Rely On TakeAim CLL Trial Progress
Analysts have sharply increased their price target on Curis, raising fair value from $14 to $280. They cite improved leadership, a more focused direct-to-consumer approach, and potential benefits from underappreciated tariff changes as key factors behind the reassessment.Recent updates
Narrative Update • Aug 04
CRIS: Future Profitability Will Depend On TakeAim CLL Study Progress
Analysts have lifted their price target on Curis to $43 from $17, citing the added valuation for emavusertib in chronic lymphocytic leukemia following the initiation of the TakeAim study and an assumed 10% probability of success on potential peak sales of $500m. Analyst Commentary Recent research on Curis highlights how much of the current valuation hinges on emavusertib and the new TakeAim study in chronic lymphocytic leukemia.Narrative Update • Jul 20
CRIS: Future Profitability Execution Will Rely On TakeAim CLL Trial Progress
Analysts have sharply increased their price target on Curis, raising fair value from $14 to $280. They cite improved leadership, a more focused direct-to-consumer approach, and potential benefits from underappreciated tariff changes as key factors behind the reassessment.
Narrative Update • Jul 06
CRIS: TakeAim CLL Progress Will Reshape Perceived Risk Profile
Analysts have sharply increased their price target on Curis to $400 from $20, citing a lower assumed discount rate, higher projected revenue growth, modestly stronger profit margins, and a slightly higher future P/E multiple as the key factors behind the updated view. Analyst Commentary on Curis Recent research updates on Curis signal a clear shift toward a more constructive stance, with bullish analysts pointing to a mix of valuation reset, growth potential, and improving execution as reasons to revisit the stock.Analysis Article • Jul 01
Curis (NASDAQ:CRIS) Will Have To Spend Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Narrative Update • Jun 22
CRIS: Future Profitability Execution Will Support Maintained 14 Fair Value
Analysts maintained their $14.00 price target for Curis, citing updated assumptions that combine a lower discount rate with higher projected revenue growth, wider profit margins and a slightly higher future P/E multiple as the main factors behind the refreshed valuation work. Analyst Commentary Recent commentary on Curis centers on how the refreshed $14.00 valuation stacks up against execution risk, profitability assumptions and the path to monetizing the company’s pipeline.
Narrative Update • Jun 05
CRIS: Expanded Share Authorization And Lower P/E Assumptions Will Support Future Upside
Analysts have raised their price target on Curis, citing updated assumptions that now include a slightly lower discount rate, a smaller expected revenue decline, a modestly higher profit margin, and a much lower future P/E multiple to support the change. Analyst Commentary Recent research on Curis points to a mixed backdrop, where some price target adjustments sit alongside a cautious tone on execution and valuation risk.Narrative Update • May 11
CRIS: Expanded Share Authorization Will Support Future Upside Despite Delisting Risks
Analysts raised their price target on Curis by $5, citing updated assumptions for revenue decline, improved profit margin expectations, a slightly lower discount rate, and a reduced future P/E estimate. Analyst Commentary Analyst reactions around Curis highlight a mix of higher price targets and upgraded ratings, but also a thread of caution around how much upside is already reflected in the stock and how execution risk could affect valuation.Narrative Update • Apr 24
CRIS: Expanded Share Authorization And Elevated Future P/E Will Support Upside
Analysts have raised the price target on Curis to $5.00 from $5.00, citing updated assumptions around discount rates, slightly less severe expected revenue contraction, lower profit margins, and a higher future P/E multiple. Analyst Commentary Recent Street research on peer names in the broader consumer space highlights how quickly sentiment can shift when expectations around earnings power, tariff exposure, and valuation multiples come under scrutiny.Narrative Update • Apr 09
CRIS: Expanded Capital Base And Elevated Future P/E Will Support Upside
Analysts have adjusted their price target on Curis to $5.00 from $5.00, citing slightly lower discount rate and revenue decline assumptions, along with a higher future P/E multiple, as key drivers of the updated view. Analyst Commentary Bearish analysts looking at Curis are focusing on how the current valuation lines up with execution risk and the assumptions baked into the updated price target.Narrative Update • Mar 26
CRIS: Expanded Capital Base And Rich Future P/E Will Support Upside
The analyst price target for Curis has been adjusted from $5 to $5.00. Analysts cite a lower discount rate, a shift to expectations of a 15.61% revenue decline, and a significantly higher assumed future P/E multiple as the main factors behind this revision.Narrative Update • Mar 11
CRIS: Maintained US$14 Fair Value Will Depend On Execution Risk
Analysts have maintained their $14.00 price target on Curis while adjusting key inputs, including a slightly lower discount rate, a revised profit margin outlook, and a higher future P/E assumption to reflect updated views on execution risk and valuation support. Analyst Commentary Analysts covering Curis are focusing less on big headline calls and more on how the updated assumptions behind the $14.00 price target line up with execution risk, profitability, and valuation support.Narrative Update • Feb 24
CRIS: Expanded Capital Base And Financing Structure Will Support Long-Term Upside
Narrative update on Curis The analyst price target for Curis has been lifted by $7, with analysts pointing to a slightly lower discount rate, modestly higher revenue growth expectations and a somewhat richer future P/E assumption as key drivers of the change. Analyst Commentary Recent Street research around comparable names highlights how quickly sentiment can swing when execution, growth visibility, or valuation do not line up cleanly.Narrative Update • Feb 10
CRIS: Maintained US$14 Fair Value Will Rely On Clinical Progress
Analysts have kept their price target for Curis steady at US$14.00. The updated view reflects slightly lower discount rate and profit margin assumptions, which are offset by a modestly reduced future P/E multiple.Narrative Update • Jan 25
CRIS: Frontline AML Data And Insider-Backed Financing Will Support Long-Term Upside
Analysts have lifted their price target on Curis to $5.00 from $5.00, citing updated assumptions around higher projected revenue growth and slightly stronger long-term profit margins, partially tempered by a higher discount rate and a lower future P/E multiple. Analyst Commentary Recent Street research on other consumer names highlights several themes that cautious investors are watching closely and that can be relevant when you think about Curis as well.Narrative Update • Jan 10
CRIS: Higher Future P/E And Clinical Progress Will Support Long Term Earnings
Analysts have raised their price target on Curis to $14.00, a change they link to updated assumptions around discount rates, revenue growth, profit margins, and a higher future P/E multiple. Analyst Commentary Analysts are applying a similar playbook across several consumer names, and that context helps explain the recent price target move on Curis.Analysis Article • Jan 04
Why Investors Shouldn't Be Surprised By Curis, Inc.'s (NASDAQ:CRIS) 27% Share Price Plunge
Unfortunately for some shareholders, the Curis, Inc. ( NASDAQ:CRIS ) share price has dived 27% in the last thirty days...Narrative Update • Dec 25
CRIS: Frontline AML Data Will Drive Long-Term Upside Despite Heightened Risk
Analysts have cut their price target on Curis from $12.00 to $5.00 as they increase the assumed discount rate, while also lifting revenue growth expectations and lowering future valuation multiples. This reflects a more cautious yet still constructive outlook on the company’s long-term earnings power.Narrative Update • Dec 11
CRIS: Reduced Risk Profile Will Support Long Term Earnings Recovery
Analysts have nudged their price target on Curis modestly higher to $14.00, citing slightly lower perceived risk and a marginally cheaper future earnings multiple. Together, these factors support a cautiously more constructive long term outlook.Narrative Update • Nov 27
CRIS: Cost Efficiencies Will Drive Earnings Recovery Despite Macro Pressures
Curis's analyst price target has been raised modestly, with analysts citing improved profit margin projections and a better cost outlook as reasons for the updated valuation of $14.00 per share. Analyst Commentary Analysts recently updated their perspectives on Curis in light of the company’s latest performance and forward-looking guidance.Analysis Article • Nov 20
Curis, Inc. (NASDAQ:CRIS) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough
The Curis, Inc. ( NASDAQ:CRIS ) share price has fared very poorly over the last month, falling by a substantial 28...Narrative Update • Nov 13
CRIS: Cost-Saving Initiatives Will Support Stronger Revenue Expansion Into 2026
Curis's analyst price target has been reduced from $16.33 to $14.00. This adjustment reflects analysts' concerns over softer profit margins, even with stronger revenue growth projections and an increased discount rate.Analysis Article • Aug 08
Curis, Inc. (NASDAQ:CRIS) Just Reported, And Analysts Assigned A US$16.33 Price Target
NasdaqCM:CRIS 1 Year Share Price vs Fair Value Explore Curis's Fair Values from the Community and select yours Curis...
New Narrative • Apr 14
FDA And EMA Will Accelerate Emavusertib Clinical Trials
Feedback from regulatory bodies can expedite market entry for emavusertib, potentially accelerating revenue and competitive advantage in the CNS lymphoma space.Analysis Article • Apr 02
Analysts Just Published A Bright New Outlook For Curis, Inc.'s (NASDAQ:CRIS)
Celebrations may be in order for Curis, Inc. ( NASDAQ:CRIS ) shareholders, with the analysts delivering a significant...Analysis Article • Apr 01
Investors Don't See Light At End Of Curis, Inc.'s (NASDAQ:CRIS) Tunnel And Push Stock Down 30%
The Curis, Inc. ( NASDAQ:CRIS ) share price has fared very poorly over the last month, falling by a substantial 30...Analysis Article • Dec 29
Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues
Unfortunately for some shareholders, the Curis, Inc. ( NASDAQ:CRIS ) share price has dived 26% in the last thirty days...Analysis Article • Nov 14
Curis, Inc.'s (NASDAQ:CRIS) 26% Dip In Price Shows Sentiment Is Matching Revenues
Curis, Inc. ( NASDAQ:CRIS ) shareholders won't be pleased to see that the share price has had a very rough month...Analysis Article • Aug 07
Growth Investors: Industry Analysts Just Upgraded Their Curis, Inc. (NASDAQ:CRIS) Revenue Forecasts By 15%
Curis, Inc. ( NASDAQ:CRIS ) shareholders will have a reason to smile today, with the analysts making substantial...Analysis Article • Aug 05
Improved Revenues Required Before Curis, Inc. (NASDAQ:CRIS) Shares Find Their Feet
With a price-to-sales (or "P/S") ratio of 2.9x Curis, Inc. ( NASDAQ:CRIS ) may be sending very bullish signals at the...Analysis Article • Apr 03
Curis, Inc. (NASDAQ:CRIS) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Curis, Inc. ( NASDAQ:CRIS ) shareholders are no doubt pleased to see that the share price has bounced 27% in the last...Shareholder Returns
| CRIS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -19.9% | 1.9% | 3.5% |
| 1Y | -88.2% | 39.1% | 20.5% |
Return vs Industry: CRIS underperformed the US Biotechs industry which returned 39.1% over the past year.
Return vs Market: CRIS underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| CRIS volatility | |
|---|---|
| CRIS Average Weekly Movement | 26.6% |
| Biotechs Industry Average Movement | 10.1% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CRIS's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CRIS's weekly volatility has increased from 17% to 26% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 22 | Jim Dentzer | www.curis.com |
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small-molecule IRAK4 kinase inhibitor, which is in a Phase 1/2 open-label, single-arm expansion trial in patients with relapsed/refractory primary central nervous system lymphoma. The company’s pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; CA-170, an oral, small-molecule antagonist designated as CA-170 that selectively targets PD-L1 and VISTA; and CA-327, an oral, small molecule, TIM3/PD-L1, which is a molecule antagonist of PD-L1 and TIM3.
Curis, Inc. Fundamentals Summary
| CRIS fundamental statistics | |
|---|---|
| Market cap | US$8.59m |
| Earnings (TTM) | -US$21.16m |
| Revenue (TTM) | US$7.06m |
1.1x
P/S Ratio-0.4x
P/E RatioIs CRIS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CRIS income statement (TTM) | |
|---|---|
| Revenue | US$7.06m |
| Cost of Revenue | US$26.31m |
| Gross Profit | -US$19.25m |
| Other Expenses | US$1.92m |
| Earnings | -US$21.16m |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -10.86 |
| Gross Margin | -272.49% |
| Net Profit Margin | -299.66% |
| Debt/Equity Ratio | 0% |
How did CRIS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/08/07 21:50 |
| End of Day Share Price | 2026/08/07 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Curis, Inc. is covered by 17 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Brian Skorney | Baird |
| James Birchenough | BMO Capital Markets Equity Research |
| Justin Walsh | B. Riley Securities, Inc. |